These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9158830)

  • 1. Atypicality revisited: further data on the effectiveness of the Mahalanobis distance in Down's syndrome screening.
    Reynolds TM
    Ann Clin Biochem; 1997 May; 34 ( Pt 3)():311-3. PubMed ID: 9158830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypicality or specific screen: which is better at detecting non-Down's chromosomal anomalies?
    Reynolds TM
    Ann Clin Biochem; 1997 Nov; 34 ( Pt 6)():675-80. PubMed ID: 9367007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
    Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
    Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of atypicality: an adjunct to prenatal screening for Down's syndrome that facilitates detection of other abnormalities.
    Wright DE; Reynolds TM; Donovan CM
    Ann Clin Biochem; 1993 Nov; 30 ( Pt 6)():578-83. PubMed ID: 7508213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Noninvasive serum test for prenatal detection of Down syndrome, other chromosome abnormalities and open neural tube defects--a prospective study].
    Zwahr C; Voss P; Kistner G
    Geburtshilfe Frauenheilkd; 1994 Jun; 54(6):355-61. PubMed ID: 7522195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antenatal screening for Down's syndrome.
    Wald NJ; Kennard A; Hackshaw A; McGuire A
    J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prenatal diagnosis of chromosome aberrations after implementation of screening for Down's syndrome].
    Kjaergaard S; Hahnemann JM; Skibsted L; Jensen LN; Sperling L; Zingenberg H; Kristiansen A; Brøndum-Nielsen K
    Ugeskr Laeger; 2008 Mar; 170(14):1152-6. PubMed ID: 18405480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of prenatal diagnosis: rapid testing or full karyotype? An audit of chromosome abnormalities and pregnancy outcomes for women referred for Down's Syndrome testing.
    Ogilvie CM; Lashwood A; Chitty L; Waters JJ; Scriven PN; Flinter F
    BJOG; 2005 Oct; 112(10):1369-75. PubMed ID: 16167939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
    Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
    N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome.
    Kadir RA; Economides DL
    Ultrasound Obstet Gynecol; 1997 Apr; 9(4):244-7. PubMed ID: 9168574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antenatal screening for Down's syndrome with the quadruple test.
    Wald NJ; Huttly WJ; Hackshaw AK
    Lancet; 2003 Mar; 361(9360):835-6. PubMed ID: 12642052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
    Wald NJ; Watt HC; Hackshaw AK
    N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal serum screening in Ontario using the triple marker test.
    Summers AM; Farrell SA; Huang T; Meier C; Wyatt PR
    J Med Screen; 2003; 10(3):107-11. PubMed ID: 14561260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
    Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
    J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down's syndrome: current screening techniques.
    White RS
    South Med J; 1989 Dec; 82(12):1483-6. PubMed ID: 2480649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal serum screening of fetal chromosomal abnormalities by AFP, UE3, hCG and free-beta hCG. Prospective and retrospective results.
    Valerio D; Aiello R; Altieri V; Fagnoni P
    Minerva Ginecol; 1996 May; 48(5):169-73. PubMed ID: 8783867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Noninvasive screening for chromosome abnormalities in young pregnant patients].
    Schmid W
    Arch Gynecol Obstet; 1992; 252 Suppl():S36-43. PubMed ID: 1482204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.